User login
News & Perspectives from Ob.Gyn. News
DRUGS, PREGNANCY, AND LACTATION
Canadian Task Force recommendation on screening for postpartum depression misses the mark
Director, Ammon-Pinizzotto Center for Women’s Mental Health at Massachusetts General Hospital, Boston, Massachusetts.
Postpartum/perinatal depression (PPD) remains the most common complication in modern obstetrics, with a prevalence of 10%-15% based on multiple studies over the last 2 decades. Over those same 2 decades, there has been growing interest and motivation across the country—from small community hospitals to major academic centers—to promote screening. Such screening is integrated into obstetrical practices, typically using the Edinburgh Postnatal Depression Scale (EPDS), the most widely used validated screen for PPD globally.
As mentioned in previous columns, the U.S. Preventive Services Task Force recommended screening for PPD in 2016, which includes screening women at highest risk, and both acutely treating and preventing PPD.
Since then, screening women for a common clinical problem like PPD has been widely adopted by clinicians representing a broad spectrum of interdisciplinary care. Providers who are engaged in the treatment of postpartum women—obstetricians, psychiatrists, doulas, lactation consultants, facilitators of postpartum support groups, and advocacy groups among others—are included.
An open question and one of great concern recently to our group and others has been what happens after screening. It is clear that identification of PPD per se is not necessarily a challenge, and we have multiple effective treatments from antidepressants to mindfulness-based cognitive therapy to cognitive-behavioral interventions. There is also a growing number of digital applications aimed at mitigation of depressive symptoms in women with postpartum major depressive disorder. One unanswered question is how to engage women after identification of PPD and how to facilitate access to care in a way that maximizes the likelihood that women who actually are suffering from PPD get adequate treatment.
The “perinatal treatment cascade” refers to the majority of women who, on the other side of identification of PPD, fail to receive adequate treatment and continue to have persistent depression. This is perhaps the greatest challenge to the field and to clinicians—how do we, on the other side of screening, see that these women get access to care and get well?
https://www.mdedge.com/obgyn/drugs-pregnancy-lactation
GENDER-AFFIRMING GYNECOLOGY
Caring for the aging transgender patient
Ob.Gyn. and fellowship-trained gender-affirming surgeon in West Reading, Pennsylvania.
The elderly transgender population is rapidly expanding and remains significantly overlooked. Although emerging evidence provides some guidance for medical and surgical treatment for transgender youth, there is still a paucity of research directed at the management of gender-diverse elders.
To a large extent, the challenges that transgender elders face are no different from those experienced by the general elder population. Irrespective of gender identity, patients begin to undergo cognitive and physical changes, encounter difficulties with activities of daily living, suffer the loss of social networks and friends, and face end-of-life issues. Attributes that contribute to successful aging in the general population include good health, social engagement and support, and having a positive outlook on life. Yet, stigma surrounding gender identity and sexual orientation continues to negatively affect elder transgender people.
https://www.mdedge.com/obgyn/gender-affirming-gynecology
Continue to: LATEST NEWS...
LATEST NEWS
Study: Prenatal supplements fail to meet nutrient needs
Although drugstore shelves might suggest otherwise,affordable dietary supplements that provide critical nutrients in appropriate doses for pregnant women are virtually nonexistent, researchers have found.
In a new study published in the American Journal of Clinical Nutrition, investigators observed what many physicians have long suspected: Most prenatal vitamins and other supplements do not adequately make up the difference of what food-based intake of nutrients leave lacking. Despite patients believing they are getting everything they need with their product purchase, they fall short of guideline-recommended requirements.
“There is no magic pill,” said Katherine A. Sauder, PhD, an associate professor of pediatrics at the University of Colorado Anschutz Medical Campus, Aurora, and lead author of the study. “There is no easy answer here.”
The researchers analyzed 24-hour dietary intake data from 2,450 study participants across five states from 2007 to 2019. Dr. Sauder and colleagues focused on six of the more than 20 key nutrients recommended for pregnant people and determined the target dose for vitamin A, vitamin D, folate, calcium, iron, and omega-3 fatty acids.
The researchers tested more than 20,500 dietary supplements, of which 421 were prenatal products. Only 69 products—three prenatal—included all six nutrients. Just seven products —two prenatal—contained target doses for five nutrients. Only one product, which was not marketed as prenatal, contained target doses for all six nutrients but required seven tablets a serving and cost patients approximately $200 a month.
SARS-CoV-2 crosses placenta and infects brains of two infants: ‘This is a first’
Researchers have found for the first time that COVID infection has crossed the placenta and caused brain damage in two newborns, according to a study published online today in Pediatrics.
One of the infants died at 13 months and the other remained in hospice care at time of manuscript submission.
Lead author Merline Benny, MD,with the division of neonatology, department of pediatrics at University of Miami, and colleagues briefed reporters today ahead of the release.
“This is a first,” said senior author Shahnaz Duara, MD, medical director of the Neonatal Intensive Care Unit at Holtz Children’s Hospital, Miami, explaining it is the first study to confirm cross-placental SARS-CoV-2 transmission leading to brain injury in a newborn.
Both infants negative for the virus at birth
The two infants were admitted in the early days of the pandemic in the Delta wave to the neonatal ICU at Holtz Children’s Hospital at University of Miami/Jackson Memorial Medical Center.
Both infants tested negative for the virus at birth, but had significantly elevated SARS-CoV-2 antibodies in their blood, indicating that either antibodies crossed the placenta, or the virus crossed and the immune response was the baby’s.
Dr. Benny explained that the researchers have seen, to this point, more than 700 mother/infant pairs in whom the mother tested positive for COVID in Jackson hospital.
Most who tested positive for COVID were asymptomatic and most of the mothers and infants left the hospital without complications.
“However, (these) two babies had a very unusual clinical picture,” Dr. Benny said.
Those infants were born to mothers who became COVID positive in the second trimester and delivered a few weeks later.
Perinatal HIV nearly eradicated in U.S.
Rates of perinatal HIV have dropped so much that the disease is effectively eliminated in the United States, with less than 1 baby for every 100,000 live births having the virus, a new study released by researchers at the Centers for Disease Control and Prevention finds.
The report marks significant progress on the U.S. government’s goal to eradicate perinatal HIV, an immune-weakening and potentially deadly virus that is passed from mother to baby during pregnancy. Just 32 children in the country were diagnosed in 2019, compared with twice as many in 2010, according to the CDC.
Mothers who are HIV positive can prevent transmission of the infection by receiving antiretroviral therapy, according to Monica Gandhi, MD, MPH, a professor of medicine at University of California, San Francisco’s division of HIV, infectious disease and global medicine.
Dr. Gandhi said she could recall only one case of perinatal HIV in the San Francisco area over the last decade.
DRUGS, PREGNANCY, AND LACTATION
Canadian Task Force recommendation on screening for postpartum depression misses the mark
Director, Ammon-Pinizzotto Center for Women’s Mental Health at Massachusetts General Hospital, Boston, Massachusetts.
Postpartum/perinatal depression (PPD) remains the most common complication in modern obstetrics, with a prevalence of 10%-15% based on multiple studies over the last 2 decades. Over those same 2 decades, there has been growing interest and motivation across the country—from small community hospitals to major academic centers—to promote screening. Such screening is integrated into obstetrical practices, typically using the Edinburgh Postnatal Depression Scale (EPDS), the most widely used validated screen for PPD globally.
As mentioned in previous columns, the U.S. Preventive Services Task Force recommended screening for PPD in 2016, which includes screening women at highest risk, and both acutely treating and preventing PPD.
Since then, screening women for a common clinical problem like PPD has been widely adopted by clinicians representing a broad spectrum of interdisciplinary care. Providers who are engaged in the treatment of postpartum women—obstetricians, psychiatrists, doulas, lactation consultants, facilitators of postpartum support groups, and advocacy groups among others—are included.
An open question and one of great concern recently to our group and others has been what happens after screening. It is clear that identification of PPD per se is not necessarily a challenge, and we have multiple effective treatments from antidepressants to mindfulness-based cognitive therapy to cognitive-behavioral interventions. There is also a growing number of digital applications aimed at mitigation of depressive symptoms in women with postpartum major depressive disorder. One unanswered question is how to engage women after identification of PPD and how to facilitate access to care in a way that maximizes the likelihood that women who actually are suffering from PPD get adequate treatment.
The “perinatal treatment cascade” refers to the majority of women who, on the other side of identification of PPD, fail to receive adequate treatment and continue to have persistent depression. This is perhaps the greatest challenge to the field and to clinicians—how do we, on the other side of screening, see that these women get access to care and get well?
https://www.mdedge.com/obgyn/drugs-pregnancy-lactation
GENDER-AFFIRMING GYNECOLOGY
Caring for the aging transgender patient
Ob.Gyn. and fellowship-trained gender-affirming surgeon in West Reading, Pennsylvania.
The elderly transgender population is rapidly expanding and remains significantly overlooked. Although emerging evidence provides some guidance for medical and surgical treatment for transgender youth, there is still a paucity of research directed at the management of gender-diverse elders.
To a large extent, the challenges that transgender elders face are no different from those experienced by the general elder population. Irrespective of gender identity, patients begin to undergo cognitive and physical changes, encounter difficulties with activities of daily living, suffer the loss of social networks and friends, and face end-of-life issues. Attributes that contribute to successful aging in the general population include good health, social engagement and support, and having a positive outlook on life. Yet, stigma surrounding gender identity and sexual orientation continues to negatively affect elder transgender people.
https://www.mdedge.com/obgyn/gender-affirming-gynecology
Continue to: LATEST NEWS...
LATEST NEWS
Study: Prenatal supplements fail to meet nutrient needs
Although drugstore shelves might suggest otherwise,affordable dietary supplements that provide critical nutrients in appropriate doses for pregnant women are virtually nonexistent, researchers have found.
In a new study published in the American Journal of Clinical Nutrition, investigators observed what many physicians have long suspected: Most prenatal vitamins and other supplements do not adequately make up the difference of what food-based intake of nutrients leave lacking. Despite patients believing they are getting everything they need with their product purchase, they fall short of guideline-recommended requirements.
“There is no magic pill,” said Katherine A. Sauder, PhD, an associate professor of pediatrics at the University of Colorado Anschutz Medical Campus, Aurora, and lead author of the study. “There is no easy answer here.”
The researchers analyzed 24-hour dietary intake data from 2,450 study participants across five states from 2007 to 2019. Dr. Sauder and colleagues focused on six of the more than 20 key nutrients recommended for pregnant people and determined the target dose for vitamin A, vitamin D, folate, calcium, iron, and omega-3 fatty acids.
The researchers tested more than 20,500 dietary supplements, of which 421 were prenatal products. Only 69 products—three prenatal—included all six nutrients. Just seven products —two prenatal—contained target doses for five nutrients. Only one product, which was not marketed as prenatal, contained target doses for all six nutrients but required seven tablets a serving and cost patients approximately $200 a month.
SARS-CoV-2 crosses placenta and infects brains of two infants: ‘This is a first’
Researchers have found for the first time that COVID infection has crossed the placenta and caused brain damage in two newborns, according to a study published online today in Pediatrics.
One of the infants died at 13 months and the other remained in hospice care at time of manuscript submission.
Lead author Merline Benny, MD,with the division of neonatology, department of pediatrics at University of Miami, and colleagues briefed reporters today ahead of the release.
“This is a first,” said senior author Shahnaz Duara, MD, medical director of the Neonatal Intensive Care Unit at Holtz Children’s Hospital, Miami, explaining it is the first study to confirm cross-placental SARS-CoV-2 transmission leading to brain injury in a newborn.
Both infants negative for the virus at birth
The two infants were admitted in the early days of the pandemic in the Delta wave to the neonatal ICU at Holtz Children’s Hospital at University of Miami/Jackson Memorial Medical Center.
Both infants tested negative for the virus at birth, but had significantly elevated SARS-CoV-2 antibodies in their blood, indicating that either antibodies crossed the placenta, or the virus crossed and the immune response was the baby’s.
Dr. Benny explained that the researchers have seen, to this point, more than 700 mother/infant pairs in whom the mother tested positive for COVID in Jackson hospital.
Most who tested positive for COVID were asymptomatic and most of the mothers and infants left the hospital without complications.
“However, (these) two babies had a very unusual clinical picture,” Dr. Benny said.
Those infants were born to mothers who became COVID positive in the second trimester and delivered a few weeks later.
Perinatal HIV nearly eradicated in U.S.
Rates of perinatal HIV have dropped so much that the disease is effectively eliminated in the United States, with less than 1 baby for every 100,000 live births having the virus, a new study released by researchers at the Centers for Disease Control and Prevention finds.
The report marks significant progress on the U.S. government’s goal to eradicate perinatal HIV, an immune-weakening and potentially deadly virus that is passed from mother to baby during pregnancy. Just 32 children in the country were diagnosed in 2019, compared with twice as many in 2010, according to the CDC.
Mothers who are HIV positive can prevent transmission of the infection by receiving antiretroviral therapy, according to Monica Gandhi, MD, MPH, a professor of medicine at University of California, San Francisco’s division of HIV, infectious disease and global medicine.
Dr. Gandhi said she could recall only one case of perinatal HIV in the San Francisco area over the last decade.
DRUGS, PREGNANCY, AND LACTATION
Canadian Task Force recommendation on screening for postpartum depression misses the mark
Director, Ammon-Pinizzotto Center for Women’s Mental Health at Massachusetts General Hospital, Boston, Massachusetts.
Postpartum/perinatal depression (PPD) remains the most common complication in modern obstetrics, with a prevalence of 10%-15% based on multiple studies over the last 2 decades. Over those same 2 decades, there has been growing interest and motivation across the country—from small community hospitals to major academic centers—to promote screening. Such screening is integrated into obstetrical practices, typically using the Edinburgh Postnatal Depression Scale (EPDS), the most widely used validated screen for PPD globally.
As mentioned in previous columns, the U.S. Preventive Services Task Force recommended screening for PPD in 2016, which includes screening women at highest risk, and both acutely treating and preventing PPD.
Since then, screening women for a common clinical problem like PPD has been widely adopted by clinicians representing a broad spectrum of interdisciplinary care. Providers who are engaged in the treatment of postpartum women—obstetricians, psychiatrists, doulas, lactation consultants, facilitators of postpartum support groups, and advocacy groups among others—are included.
An open question and one of great concern recently to our group and others has been what happens after screening. It is clear that identification of PPD per se is not necessarily a challenge, and we have multiple effective treatments from antidepressants to mindfulness-based cognitive therapy to cognitive-behavioral interventions. There is also a growing number of digital applications aimed at mitigation of depressive symptoms in women with postpartum major depressive disorder. One unanswered question is how to engage women after identification of PPD and how to facilitate access to care in a way that maximizes the likelihood that women who actually are suffering from PPD get adequate treatment.
The “perinatal treatment cascade” refers to the majority of women who, on the other side of identification of PPD, fail to receive adequate treatment and continue to have persistent depression. This is perhaps the greatest challenge to the field and to clinicians—how do we, on the other side of screening, see that these women get access to care and get well?
https://www.mdedge.com/obgyn/drugs-pregnancy-lactation
GENDER-AFFIRMING GYNECOLOGY
Caring for the aging transgender patient
Ob.Gyn. and fellowship-trained gender-affirming surgeon in West Reading, Pennsylvania.
The elderly transgender population is rapidly expanding and remains significantly overlooked. Although emerging evidence provides some guidance for medical and surgical treatment for transgender youth, there is still a paucity of research directed at the management of gender-diverse elders.
To a large extent, the challenges that transgender elders face are no different from those experienced by the general elder population. Irrespective of gender identity, patients begin to undergo cognitive and physical changes, encounter difficulties with activities of daily living, suffer the loss of social networks and friends, and face end-of-life issues. Attributes that contribute to successful aging in the general population include good health, social engagement and support, and having a positive outlook on life. Yet, stigma surrounding gender identity and sexual orientation continues to negatively affect elder transgender people.
https://www.mdedge.com/obgyn/gender-affirming-gynecology
Continue to: LATEST NEWS...
LATEST NEWS
Study: Prenatal supplements fail to meet nutrient needs
Although drugstore shelves might suggest otherwise,affordable dietary supplements that provide critical nutrients in appropriate doses for pregnant women are virtually nonexistent, researchers have found.
In a new study published in the American Journal of Clinical Nutrition, investigators observed what many physicians have long suspected: Most prenatal vitamins and other supplements do not adequately make up the difference of what food-based intake of nutrients leave lacking. Despite patients believing they are getting everything they need with their product purchase, they fall short of guideline-recommended requirements.
“There is no magic pill,” said Katherine A. Sauder, PhD, an associate professor of pediatrics at the University of Colorado Anschutz Medical Campus, Aurora, and lead author of the study. “There is no easy answer here.”
The researchers analyzed 24-hour dietary intake data from 2,450 study participants across five states from 2007 to 2019. Dr. Sauder and colleagues focused on six of the more than 20 key nutrients recommended for pregnant people and determined the target dose for vitamin A, vitamin D, folate, calcium, iron, and omega-3 fatty acids.
The researchers tested more than 20,500 dietary supplements, of which 421 were prenatal products. Only 69 products—three prenatal—included all six nutrients. Just seven products —two prenatal—contained target doses for five nutrients. Only one product, which was not marketed as prenatal, contained target doses for all six nutrients but required seven tablets a serving and cost patients approximately $200 a month.
SARS-CoV-2 crosses placenta and infects brains of two infants: ‘This is a first’
Researchers have found for the first time that COVID infection has crossed the placenta and caused brain damage in two newborns, according to a study published online today in Pediatrics.
One of the infants died at 13 months and the other remained in hospice care at time of manuscript submission.
Lead author Merline Benny, MD,with the division of neonatology, department of pediatrics at University of Miami, and colleagues briefed reporters today ahead of the release.
“This is a first,” said senior author Shahnaz Duara, MD, medical director of the Neonatal Intensive Care Unit at Holtz Children’s Hospital, Miami, explaining it is the first study to confirm cross-placental SARS-CoV-2 transmission leading to brain injury in a newborn.
Both infants negative for the virus at birth
The two infants were admitted in the early days of the pandemic in the Delta wave to the neonatal ICU at Holtz Children’s Hospital at University of Miami/Jackson Memorial Medical Center.
Both infants tested negative for the virus at birth, but had significantly elevated SARS-CoV-2 antibodies in their blood, indicating that either antibodies crossed the placenta, or the virus crossed and the immune response was the baby’s.
Dr. Benny explained that the researchers have seen, to this point, more than 700 mother/infant pairs in whom the mother tested positive for COVID in Jackson hospital.
Most who tested positive for COVID were asymptomatic and most of the mothers and infants left the hospital without complications.
“However, (these) two babies had a very unusual clinical picture,” Dr. Benny said.
Those infants were born to mothers who became COVID positive in the second trimester and delivered a few weeks later.
Perinatal HIV nearly eradicated in U.S.
Rates of perinatal HIV have dropped so much that the disease is effectively eliminated in the United States, with less than 1 baby for every 100,000 live births having the virus, a new study released by researchers at the Centers for Disease Control and Prevention finds.
The report marks significant progress on the U.S. government’s goal to eradicate perinatal HIV, an immune-weakening and potentially deadly virus that is passed from mother to baby during pregnancy. Just 32 children in the country were diagnosed in 2019, compared with twice as many in 2010, according to the CDC.
Mothers who are HIV positive can prevent transmission of the infection by receiving antiretroviral therapy, according to Monica Gandhi, MD, MPH, a professor of medicine at University of California, San Francisco’s division of HIV, infectious disease and global medicine.
Dr. Gandhi said she could recall only one case of perinatal HIV in the San Francisco area over the last decade.
Independent risk factors-based referral tool may help identify PsA in psoriasis
Key clinical point: A referral tool based on five independent risk factors for concomitant psoriatic arthritis (PsA) among patients with psoriasis may help dermatologists to identify patients with psoriasis who could benefit from a rheumatologist referral.
Major finding: The predictive variables for concomitant PsA among patients with psoriasis that were included in the referral tool were treatment history with conventional systemics (P = .04) and biologics/small molecule inhibitors (P = .01), patient-reported history of joint pain without trauma (P = .02), swollen joints (P < .001), and sausage-like swollen digits (P = .01). The referral tool had an area under curve of 0.82.
Study details: This study analyzed the data of 303 patients with psoriasis from the prospective observational DAPPER study who had visited the dermatology outpatient clinic.
Disclosures: This study was funded by a PhD grant from Radboud University Medical Center/Sint Maartenskliniek, Netherlands, and local structural research funding of the Sint Maartenskliniek. Several authors reported financial and non-financial ties with various sources.
Source: van Hal TW et al. Development of a new referral tool to identify psoriasis patients with concomitant psoriatic arthritis: Results of the prospective DAPPER cohort. Acta Derm Venereol. 2023 (Apr 27). Doi: 10.2340/actadv.v103.5269
Key clinical point: A referral tool based on five independent risk factors for concomitant psoriatic arthritis (PsA) among patients with psoriasis may help dermatologists to identify patients with psoriasis who could benefit from a rheumatologist referral.
Major finding: The predictive variables for concomitant PsA among patients with psoriasis that were included in the referral tool were treatment history with conventional systemics (P = .04) and biologics/small molecule inhibitors (P = .01), patient-reported history of joint pain without trauma (P = .02), swollen joints (P < .001), and sausage-like swollen digits (P = .01). The referral tool had an area under curve of 0.82.
Study details: This study analyzed the data of 303 patients with psoriasis from the prospective observational DAPPER study who had visited the dermatology outpatient clinic.
Disclosures: This study was funded by a PhD grant from Radboud University Medical Center/Sint Maartenskliniek, Netherlands, and local structural research funding of the Sint Maartenskliniek. Several authors reported financial and non-financial ties with various sources.
Source: van Hal TW et al. Development of a new referral tool to identify psoriasis patients with concomitant psoriatic arthritis: Results of the prospective DAPPER cohort. Acta Derm Venereol. 2023 (Apr 27). Doi: 10.2340/actadv.v103.5269
Key clinical point: A referral tool based on five independent risk factors for concomitant psoriatic arthritis (PsA) among patients with psoriasis may help dermatologists to identify patients with psoriasis who could benefit from a rheumatologist referral.
Major finding: The predictive variables for concomitant PsA among patients with psoriasis that were included in the referral tool were treatment history with conventional systemics (P = .04) and biologics/small molecule inhibitors (P = .01), patient-reported history of joint pain without trauma (P = .02), swollen joints (P < .001), and sausage-like swollen digits (P = .01). The referral tool had an area under curve of 0.82.
Study details: This study analyzed the data of 303 patients with psoriasis from the prospective observational DAPPER study who had visited the dermatology outpatient clinic.
Disclosures: This study was funded by a PhD grant from Radboud University Medical Center/Sint Maartenskliniek, Netherlands, and local structural research funding of the Sint Maartenskliniek. Several authors reported financial and non-financial ties with various sources.
Source: van Hal TW et al. Development of a new referral tool to identify psoriasis patients with concomitant psoriatic arthritis: Results of the prospective DAPPER cohort. Acta Derm Venereol. 2023 (Apr 27). Doi: 10.2340/actadv.v103.5269
Low extent and incidence of radiographic spinal damage in PsA vs spondyloarthritis
Key clinical point: The occurrence of radiographic spinal damage was overall low among patients with psoriatic arthritis (PsA) and spondyloarthritis; however, severe spinal damage and the extent of syndesmophytes led spinal damage were more observed in spondyloarthritis vs PsA.
Major finding: Proportion of patients with PsA vs spondyloarthritis experiencing spinal damage was comparable (10.6% vs 7.9%; P = .320). However, patients with spondyloarthritis and spinal damage vs PsA had higher modified Stoke Ankylosing Spondylitis Spine Scores, indicating severe spinal damage (P < .05). Syndesmophytes were significantly higher in the total spine of patients with spondyloarthritis vs PsA (P < .05).
Study details: This study evaluated patients with PsA (n = 312) and spondyloarthritis (n = 213) who had undergone radiographic imaging assessment in the Belgian Epidemiological Psoriatic Arthritis Study (BEPAS) and observational Ghent and Belgian Inflammatory Arthritis and Spondylitis (Be-GIANT) study, respectively.
Disclosures: The BEPAS and Be-GIANT studies were funded by Merck Sharp Dohme Belgium and AbbVie, respectively. Several authors reported ties with various companies, including AbbVie or Merck Sharp Dohme.
Source: de Hooge M et al. Extent of axial damage in psoriatic arthritis and spondyloarthritis: Comparative data from the BEPAS and (Be-)GIANT multicentre cohorts. RMD Open. 2023;9(2):e002994 (May 3). Doi: 10.1136/rmdopen-2023-002994
Key clinical point: The occurrence of radiographic spinal damage was overall low among patients with psoriatic arthritis (PsA) and spondyloarthritis; however, severe spinal damage and the extent of syndesmophytes led spinal damage were more observed in spondyloarthritis vs PsA.
Major finding: Proportion of patients with PsA vs spondyloarthritis experiencing spinal damage was comparable (10.6% vs 7.9%; P = .320). However, patients with spondyloarthritis and spinal damage vs PsA had higher modified Stoke Ankylosing Spondylitis Spine Scores, indicating severe spinal damage (P < .05). Syndesmophytes were significantly higher in the total spine of patients with spondyloarthritis vs PsA (P < .05).
Study details: This study evaluated patients with PsA (n = 312) and spondyloarthritis (n = 213) who had undergone radiographic imaging assessment in the Belgian Epidemiological Psoriatic Arthritis Study (BEPAS) and observational Ghent and Belgian Inflammatory Arthritis and Spondylitis (Be-GIANT) study, respectively.
Disclosures: The BEPAS and Be-GIANT studies were funded by Merck Sharp Dohme Belgium and AbbVie, respectively. Several authors reported ties with various companies, including AbbVie or Merck Sharp Dohme.
Source: de Hooge M et al. Extent of axial damage in psoriatic arthritis and spondyloarthritis: Comparative data from the BEPAS and (Be-)GIANT multicentre cohorts. RMD Open. 2023;9(2):e002994 (May 3). Doi: 10.1136/rmdopen-2023-002994
Key clinical point: The occurrence of radiographic spinal damage was overall low among patients with psoriatic arthritis (PsA) and spondyloarthritis; however, severe spinal damage and the extent of syndesmophytes led spinal damage were more observed in spondyloarthritis vs PsA.
Major finding: Proportion of patients with PsA vs spondyloarthritis experiencing spinal damage was comparable (10.6% vs 7.9%; P = .320). However, patients with spondyloarthritis and spinal damage vs PsA had higher modified Stoke Ankylosing Spondylitis Spine Scores, indicating severe spinal damage (P < .05). Syndesmophytes were significantly higher in the total spine of patients with spondyloarthritis vs PsA (P < .05).
Study details: This study evaluated patients with PsA (n = 312) and spondyloarthritis (n = 213) who had undergone radiographic imaging assessment in the Belgian Epidemiological Psoriatic Arthritis Study (BEPAS) and observational Ghent and Belgian Inflammatory Arthritis and Spondylitis (Be-GIANT) study, respectively.
Disclosures: The BEPAS and Be-GIANT studies were funded by Merck Sharp Dohme Belgium and AbbVie, respectively. Several authors reported ties with various companies, including AbbVie or Merck Sharp Dohme.
Source: de Hooge M et al. Extent of axial damage in psoriatic arthritis and spondyloarthritis: Comparative data from the BEPAS and (Be-)GIANT multicentre cohorts. RMD Open. 2023;9(2):e002994 (May 3). Doi: 10.1136/rmdopen-2023-002994
Interleukin-17A inhibitor secukinumab safe and effective in oligoarticular PsA
Key clinical point: Secukinumab reduced disease activity at week 12, which sustained or improved by week 52, and demonstrated a consistent safety profile in patients with oligoarticular psoriatic arthritis (PsA).
Major finding: At week 12, 50% improvement in Disease Activity Index for Psoriatic Arthritis (DAPSA50) was achieved by a higher proportion of patients treated with 300 mg or 150 mg secukinumab vs placebo-treated patients (65.2% and 44.4% vs 30.0%, respectively). DAPSA50 responses further improved with 300 mg and 150 mg secukinumab at week 52 (74.2% and 71.8%; respectively). The safety profile of secukinumab was consistent with that reported in the original trials.
Study details: This post hoc analysis of the phase 3/3b FUTURE 2-5 and MAXIMISE trials included 84 patients with oligoarticular PsA who were randomly assigned to receive 150 or 300 mg secukinumab or placebo until week 12 and 150 or 300 mg `secukinumab from week 12 to 52.
Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. Some authors declared being employees and holding stocks or shares or having other ties with Novartis or others.
Source: Ogdie A et al. Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis. Rheumatol Ther. 2023 (May 6). Doi: 10.1007/s40744-023-00548-y
Key clinical point: Secukinumab reduced disease activity at week 12, which sustained or improved by week 52, and demonstrated a consistent safety profile in patients with oligoarticular psoriatic arthritis (PsA).
Major finding: At week 12, 50% improvement in Disease Activity Index for Psoriatic Arthritis (DAPSA50) was achieved by a higher proportion of patients treated with 300 mg or 150 mg secukinumab vs placebo-treated patients (65.2% and 44.4% vs 30.0%, respectively). DAPSA50 responses further improved with 300 mg and 150 mg secukinumab at week 52 (74.2% and 71.8%; respectively). The safety profile of secukinumab was consistent with that reported in the original trials.
Study details: This post hoc analysis of the phase 3/3b FUTURE 2-5 and MAXIMISE trials included 84 patients with oligoarticular PsA who were randomly assigned to receive 150 or 300 mg secukinumab or placebo until week 12 and 150 or 300 mg `secukinumab from week 12 to 52.
Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. Some authors declared being employees and holding stocks or shares or having other ties with Novartis or others.
Source: Ogdie A et al. Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis. Rheumatol Ther. 2023 (May 6). Doi: 10.1007/s40744-023-00548-y
Key clinical point: Secukinumab reduced disease activity at week 12, which sustained or improved by week 52, and demonstrated a consistent safety profile in patients with oligoarticular psoriatic arthritis (PsA).
Major finding: At week 12, 50% improvement in Disease Activity Index for Psoriatic Arthritis (DAPSA50) was achieved by a higher proportion of patients treated with 300 mg or 150 mg secukinumab vs placebo-treated patients (65.2% and 44.4% vs 30.0%, respectively). DAPSA50 responses further improved with 300 mg and 150 mg secukinumab at week 52 (74.2% and 71.8%; respectively). The safety profile of secukinumab was consistent with that reported in the original trials.
Study details: This post hoc analysis of the phase 3/3b FUTURE 2-5 and MAXIMISE trials included 84 patients with oligoarticular PsA who were randomly assigned to receive 150 or 300 mg secukinumab or placebo until week 12 and 150 or 300 mg `secukinumab from week 12 to 52.
Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. Some authors declared being employees and holding stocks or shares or having other ties with Novartis or others.
Source: Ogdie A et al. Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis. Rheumatol Ther. 2023 (May 6). Doi: 10.1007/s40744-023-00548-y
Pretreatment systemic inflammatory markers may guide therapeutic approach in PsA
Key clinical point: Patients with higher platelet lymphocyte ratio (PLR) or C-reactive protein (CRP) levels were more likely to be diagnosed with psoriatic arthritis (PsA) than psoriasis vulgaris (PsV), with patients having higher pretreatment systemic inflammatory marker scores showing lower treatment persistence with conventional therapies.
Major finding: PLR (odds ratio [OR] 7.027; P = .040) or CRP levels (OR 3.179; P = .022) at the time of initial presentation were associated with a higher probability of PsA vs PsV diagnosis, with patients having higher pretreatment platelet or neutrophil counts, PLR, and systemic immune/inflammation index scores exhibiting lower treatment continuation rates for conventional systemic agents (all P < .05).
Study details: Findings are from a retrospective analysis including patients with PsA (n = 47) and PsV (n = 117) and control individuals with no history of allergy or skin diseases (n = 50).
Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.
Source: Sugimoto E, Matsuda H, et al. Impact of pretreatment systemic inflammatory markers on treatment persistence with biologics and conventional systemic therapy: A retrospective study of patients with psoriasis vulgaris and psoriatic arthritis. J Clin Med. 2023;12(8):3046 (Apr 21). Doi: 10.3390/jcm12083046
Key clinical point: Patients with higher platelet lymphocyte ratio (PLR) or C-reactive protein (CRP) levels were more likely to be diagnosed with psoriatic arthritis (PsA) than psoriasis vulgaris (PsV), with patients having higher pretreatment systemic inflammatory marker scores showing lower treatment persistence with conventional therapies.
Major finding: PLR (odds ratio [OR] 7.027; P = .040) or CRP levels (OR 3.179; P = .022) at the time of initial presentation were associated with a higher probability of PsA vs PsV diagnosis, with patients having higher pretreatment platelet or neutrophil counts, PLR, and systemic immune/inflammation index scores exhibiting lower treatment continuation rates for conventional systemic agents (all P < .05).
Study details: Findings are from a retrospective analysis including patients with PsA (n = 47) and PsV (n = 117) and control individuals with no history of allergy or skin diseases (n = 50).
Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.
Source: Sugimoto E, Matsuda H, et al. Impact of pretreatment systemic inflammatory markers on treatment persistence with biologics and conventional systemic therapy: A retrospective study of patients with psoriasis vulgaris and psoriatic arthritis. J Clin Med. 2023;12(8):3046 (Apr 21). Doi: 10.3390/jcm12083046
Key clinical point: Patients with higher platelet lymphocyte ratio (PLR) or C-reactive protein (CRP) levels were more likely to be diagnosed with psoriatic arthritis (PsA) than psoriasis vulgaris (PsV), with patients having higher pretreatment systemic inflammatory marker scores showing lower treatment persistence with conventional therapies.
Major finding: PLR (odds ratio [OR] 7.027; P = .040) or CRP levels (OR 3.179; P = .022) at the time of initial presentation were associated with a higher probability of PsA vs PsV diagnosis, with patients having higher pretreatment platelet or neutrophil counts, PLR, and systemic immune/inflammation index scores exhibiting lower treatment continuation rates for conventional systemic agents (all P < .05).
Study details: Findings are from a retrospective analysis including patients with PsA (n = 47) and PsV (n = 117) and control individuals with no history of allergy or skin diseases (n = 50).
Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.
Source: Sugimoto E, Matsuda H, et al. Impact of pretreatment systemic inflammatory markers on treatment persistence with biologics and conventional systemic therapy: A retrospective study of patients with psoriasis vulgaris and psoriatic arthritis. J Clin Med. 2023;12(8):3046 (Apr 21). Doi: 10.3390/jcm12083046
Concomitant methotrexate has no effect on ustekinumab immunogenicity in PsA
Key clinical point: Concomitant methotrexate had no effect on ustekimumab immunogenicity in patients with psoriatic arthritis (PsA), with the formation of antidrug antibody (ADA) not being associated with reductions in ustekinumab safety or efficacy.
Major finding: The prevalence of ADA at week 52 was not significantly different between the ustekinumab+methotrexate and ustekinumab+placebo groups, with disease activity, treatment response, dropout rates, effect of pretreatment with methotrexate, and safety outcomes not being significantly different in patients with vs without ADA (all P > .05).
Study details: This post hoc analysis of the MUST trial included 112 patients with active PsA who were naive to ustekimumab and were randomly assigned to receive ustekinumab with concomitant methotrexate or placebo.
Disclosures: This study was funded by Innovative Medicines Initiative 2 Joint Undertaking, which received support from the European Union’s Horizon 2020 Research and Innovation Program and others. F Behrens, M Koehm, and H Burkhardt declared receiving research grants from Janssen Cilag. The other authors reported no conflicts of interest.
Source: Poor SM et al. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate. Rheumatology (Oxford). 2023 (Apr 20). Doi: 10.1093/rheumatology/kead177
Key clinical point: Concomitant methotrexate had no effect on ustekimumab immunogenicity in patients with psoriatic arthritis (PsA), with the formation of antidrug antibody (ADA) not being associated with reductions in ustekinumab safety or efficacy.
Major finding: The prevalence of ADA at week 52 was not significantly different between the ustekinumab+methotrexate and ustekinumab+placebo groups, with disease activity, treatment response, dropout rates, effect of pretreatment with methotrexate, and safety outcomes not being significantly different in patients with vs without ADA (all P > .05).
Study details: This post hoc analysis of the MUST trial included 112 patients with active PsA who were naive to ustekimumab and were randomly assigned to receive ustekinumab with concomitant methotrexate or placebo.
Disclosures: This study was funded by Innovative Medicines Initiative 2 Joint Undertaking, which received support from the European Union’s Horizon 2020 Research and Innovation Program and others. F Behrens, M Koehm, and H Burkhardt declared receiving research grants from Janssen Cilag. The other authors reported no conflicts of interest.
Source: Poor SM et al. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate. Rheumatology (Oxford). 2023 (Apr 20). Doi: 10.1093/rheumatology/kead177
Key clinical point: Concomitant methotrexate had no effect on ustekimumab immunogenicity in patients with psoriatic arthritis (PsA), with the formation of antidrug antibody (ADA) not being associated with reductions in ustekinumab safety or efficacy.
Major finding: The prevalence of ADA at week 52 was not significantly different between the ustekinumab+methotrexate and ustekinumab+placebo groups, with disease activity, treatment response, dropout rates, effect of pretreatment with methotrexate, and safety outcomes not being significantly different in patients with vs without ADA (all P > .05).
Study details: This post hoc analysis of the MUST trial included 112 patients with active PsA who were naive to ustekimumab and were randomly assigned to receive ustekinumab with concomitant methotrexate or placebo.
Disclosures: This study was funded by Innovative Medicines Initiative 2 Joint Undertaking, which received support from the European Union’s Horizon 2020 Research and Innovation Program and others. F Behrens, M Koehm, and H Burkhardt declared receiving research grants from Janssen Cilag. The other authors reported no conflicts of interest.
Source: Poor SM et al. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate. Rheumatology (Oxford). 2023 (Apr 20). Doi: 10.1093/rheumatology/kead177
Entheseal fibrocartilage abnormalities: A potential imaging biomarker of PsA
Key clinical point: The entheseal fibrocartilage (EF) thickness assessed during power Doppler ultrasound evaluation was significantly different among patients with psoriatic arthritis (PsA) and control individuals and can be explored as an imaging biomarker for PsA.
Major finding: The median EF thickness was significantly greater in patients with PsA and athletes vs control individuals (0.035 and 0.036 vs 0.030 cm, respectively; P = .05 and P = .008, respectively), with the intra- and inter-reader reliability of the evaluation of EF thickness being excellent (intraclass correlation coefficient [ICC] 0.91) and good (ICC 0.80; both P < .001), respectively.
Study details: This cross-sectional study included patients with PsA (n = 30), athletes (n = 40), and control individuals (n = 20) who underwent power Doppler ultrasound evaluation during bilateral Achilles tendon insertions.
Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.
Source: Perrotta FM et al. Ultrasonographic evaluation of entheseal fibrocartilage in patients with psoriatic arthritis, athletes and healthy controls: A comparison study. Diagnostics (Basel). 2023;13(8):1446 (Apr 17). Doi: 10.3390/diagnostics13081446
Key clinical point: The entheseal fibrocartilage (EF) thickness assessed during power Doppler ultrasound evaluation was significantly different among patients with psoriatic arthritis (PsA) and control individuals and can be explored as an imaging biomarker for PsA.
Major finding: The median EF thickness was significantly greater in patients with PsA and athletes vs control individuals (0.035 and 0.036 vs 0.030 cm, respectively; P = .05 and P = .008, respectively), with the intra- and inter-reader reliability of the evaluation of EF thickness being excellent (intraclass correlation coefficient [ICC] 0.91) and good (ICC 0.80; both P < .001), respectively.
Study details: This cross-sectional study included patients with PsA (n = 30), athletes (n = 40), and control individuals (n = 20) who underwent power Doppler ultrasound evaluation during bilateral Achilles tendon insertions.
Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.
Source: Perrotta FM et al. Ultrasonographic evaluation of entheseal fibrocartilage in patients with psoriatic arthritis, athletes and healthy controls: A comparison study. Diagnostics (Basel). 2023;13(8):1446 (Apr 17). Doi: 10.3390/diagnostics13081446
Key clinical point: The entheseal fibrocartilage (EF) thickness assessed during power Doppler ultrasound evaluation was significantly different among patients with psoriatic arthritis (PsA) and control individuals and can be explored as an imaging biomarker for PsA.
Major finding: The median EF thickness was significantly greater in patients with PsA and athletes vs control individuals (0.035 and 0.036 vs 0.030 cm, respectively; P = .05 and P = .008, respectively), with the intra- and inter-reader reliability of the evaluation of EF thickness being excellent (intraclass correlation coefficient [ICC] 0.91) and good (ICC 0.80; both P < .001), respectively.
Study details: This cross-sectional study included patients with PsA (n = 30), athletes (n = 40), and control individuals (n = 20) who underwent power Doppler ultrasound evaluation during bilateral Achilles tendon insertions.
Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.
Source: Perrotta FM et al. Ultrasonographic evaluation of entheseal fibrocartilage in patients with psoriatic arthritis, athletes and healthy controls: A comparison study. Diagnostics (Basel). 2023;13(8):1446 (Apr 17). Doi: 10.3390/diagnostics13081446
Upadacitinib safe and effective in PsA patients with axial involvement
Key clinical point: Compared with placebo, 15 mg upadacitinib led to a greater improvement in axial symptoms with a consistent safety profile in patients with psoriatic arthritis (PsA).
Major finding: The improvement in overall Bath Ankylosing Spondylitis Disease Activity Index score at week 24 was significantly higher with 15 mg upadacitinib vs placebo in both SELECT-PsA 1 (−3.12 vs −1.70; P < .0001) and SELECT PsA 2 (−2.06 vs −0.21; P < .0001) trials. Treatment-emergent adverse events were generally similar among the sub-groups.
Study details: This post hoc analysis included patients with active PsA (n = 1,281 and n = 423, respectively) from the SELECT-PsA 1 and SELECT-PsA 2 trials who were randomly assigned to receive either 15 mg upadacitinib, placebo, or adalimumab and were categorized as those with or without axial involvement.
Disclosures: This study was funded by AbbVie. Five authors declared being employees or stockholders of AbbVie, and some authors reported ties with various sources, including AbbVie.
Source: Baraliakos X et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: Results from two phase 3 studies. Arthritis Res Ther. 2023;25:56 (Apr 10). Doi: 10.1186/s13075-023-03027-5
Key clinical point: Compared with placebo, 15 mg upadacitinib led to a greater improvement in axial symptoms with a consistent safety profile in patients with psoriatic arthritis (PsA).
Major finding: The improvement in overall Bath Ankylosing Spondylitis Disease Activity Index score at week 24 was significantly higher with 15 mg upadacitinib vs placebo in both SELECT-PsA 1 (−3.12 vs −1.70; P < .0001) and SELECT PsA 2 (−2.06 vs −0.21; P < .0001) trials. Treatment-emergent adverse events were generally similar among the sub-groups.
Study details: This post hoc analysis included patients with active PsA (n = 1,281 and n = 423, respectively) from the SELECT-PsA 1 and SELECT-PsA 2 trials who were randomly assigned to receive either 15 mg upadacitinib, placebo, or adalimumab and were categorized as those with or without axial involvement.
Disclosures: This study was funded by AbbVie. Five authors declared being employees or stockholders of AbbVie, and some authors reported ties with various sources, including AbbVie.
Source: Baraliakos X et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: Results from two phase 3 studies. Arthritis Res Ther. 2023;25:56 (Apr 10). Doi: 10.1186/s13075-023-03027-5
Key clinical point: Compared with placebo, 15 mg upadacitinib led to a greater improvement in axial symptoms with a consistent safety profile in patients with psoriatic arthritis (PsA).
Major finding: The improvement in overall Bath Ankylosing Spondylitis Disease Activity Index score at week 24 was significantly higher with 15 mg upadacitinib vs placebo in both SELECT-PsA 1 (−3.12 vs −1.70; P < .0001) and SELECT PsA 2 (−2.06 vs −0.21; P < .0001) trials. Treatment-emergent adverse events were generally similar among the sub-groups.
Study details: This post hoc analysis included patients with active PsA (n = 1,281 and n = 423, respectively) from the SELECT-PsA 1 and SELECT-PsA 2 trials who were randomly assigned to receive either 15 mg upadacitinib, placebo, or adalimumab and were categorized as those with or without axial involvement.
Disclosures: This study was funded by AbbVie. Five authors declared being employees or stockholders of AbbVie, and some authors reported ties with various sources, including AbbVie.
Source: Baraliakos X et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: Results from two phase 3 studies. Arthritis Res Ther. 2023;25:56 (Apr 10). Doi: 10.1186/s13075-023-03027-5
Sonographic enthesitis associated with sonographic synovitis and tenosynovitis in PsA
Key clinical point: Sonographic enthesitis showed strong association with sonographic synovitis and tenosynovitis in patients with psoriatic arthritis (PsA), suggesting the clinical significance of sonographic enthesitis as a potential marker for inflammation in other musculoskeletal domains.
Major finding: Sonographic enthesitis was significantly associated with sonographic synovitis (β 0.19; P = .004) and sonographic tenosynovitis (β 0.1; P = .003) and showed strong correlation with patient-reported outcomes, such as Health Assessment Questionnaire (P = .003), morning stiffness (P = .002), and others.
Study details: This study prospectively recruited 158 patients with PsA who underwent sonographic assessment of 52 joints, 40 tendons, and 14 entheses points along with clinical evaluation.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Balulu G et al. The association between sonographic enthesitis with sonographic synovitis and tenosynovitis in psoriatic arthritis patients. Rheumatology (Oxford). 2023 (May 11). Doi: 10.1093/rheumatology/kead202
Key clinical point: Sonographic enthesitis showed strong association with sonographic synovitis and tenosynovitis in patients with psoriatic arthritis (PsA), suggesting the clinical significance of sonographic enthesitis as a potential marker for inflammation in other musculoskeletal domains.
Major finding: Sonographic enthesitis was significantly associated with sonographic synovitis (β 0.19; P = .004) and sonographic tenosynovitis (β 0.1; P = .003) and showed strong correlation with patient-reported outcomes, such as Health Assessment Questionnaire (P = .003), morning stiffness (P = .002), and others.
Study details: This study prospectively recruited 158 patients with PsA who underwent sonographic assessment of 52 joints, 40 tendons, and 14 entheses points along with clinical evaluation.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Balulu G et al. The association between sonographic enthesitis with sonographic synovitis and tenosynovitis in psoriatic arthritis patients. Rheumatology (Oxford). 2023 (May 11). Doi: 10.1093/rheumatology/kead202
Key clinical point: Sonographic enthesitis showed strong association with sonographic synovitis and tenosynovitis in patients with psoriatic arthritis (PsA), suggesting the clinical significance of sonographic enthesitis as a potential marker for inflammation in other musculoskeletal domains.
Major finding: Sonographic enthesitis was significantly associated with sonographic synovitis (β 0.19; P = .004) and sonographic tenosynovitis (β 0.1; P = .003) and showed strong correlation with patient-reported outcomes, such as Health Assessment Questionnaire (P = .003), morning stiffness (P = .002), and others.
Study details: This study prospectively recruited 158 patients with PsA who underwent sonographic assessment of 52 joints, 40 tendons, and 14 entheses points along with clinical evaluation.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Balulu G et al. The association between sonographic enthesitis with sonographic synovitis and tenosynovitis in psoriatic arthritis patients. Rheumatology (Oxford). 2023 (May 11). Doi: 10.1093/rheumatology/kead202
Enthesitis resolution similar with secukinumab and adalimumab in PsA
Key clinical point: Patients with psoriatic arthritis (PsA) achieved enthesitis resolution over 52 weeks with secukinumab treatment, which was comparable to that with adalimumab treatment.
Major finding: At week 52, secukinumab vs adalimumab led to a similar proportion of patients achieving enthesitis resolution (53.2% vs 51.4%) along with site-specific resolution of lateral epicondyle enthesitis (84.6% vs 87.1%) and showing relapse after first resolution (21.0% vs 15.6%), as assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Moreover, secukinumab vs adalimumab had a comparable response time to SPARCC enthesitis resolution (113 vs 88 days).
Study details: This post hoc analysis of the EXCEED study included 853 patients with PsA who received either secukinumab (300 mg) or adalimumab (40 mg) over 52 weeks.
Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, USA. C Gaillez and B Parikh declared being current or former employees of Novartis Pharma or Novartis Pharmaceuticals Corporation, and several authors reported ties with various sources, including Novartis.
Source: Kaeley GS et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: A post hoc analysis of the EXCEED study. Rheumatology (Oxford). 2023 (Apr 25). Doi: 10.1093/rheumatology/kead181
Key clinical point: Patients with psoriatic arthritis (PsA) achieved enthesitis resolution over 52 weeks with secukinumab treatment, which was comparable to that with adalimumab treatment.
Major finding: At week 52, secukinumab vs adalimumab led to a similar proportion of patients achieving enthesitis resolution (53.2% vs 51.4%) along with site-specific resolution of lateral epicondyle enthesitis (84.6% vs 87.1%) and showing relapse after first resolution (21.0% vs 15.6%), as assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Moreover, secukinumab vs adalimumab had a comparable response time to SPARCC enthesitis resolution (113 vs 88 days).
Study details: This post hoc analysis of the EXCEED study included 853 patients with PsA who received either secukinumab (300 mg) or adalimumab (40 mg) over 52 weeks.
Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, USA. C Gaillez and B Parikh declared being current or former employees of Novartis Pharma or Novartis Pharmaceuticals Corporation, and several authors reported ties with various sources, including Novartis.
Source: Kaeley GS et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: A post hoc analysis of the EXCEED study. Rheumatology (Oxford). 2023 (Apr 25). Doi: 10.1093/rheumatology/kead181
Key clinical point: Patients with psoriatic arthritis (PsA) achieved enthesitis resolution over 52 weeks with secukinumab treatment, which was comparable to that with adalimumab treatment.
Major finding: At week 52, secukinumab vs adalimumab led to a similar proportion of patients achieving enthesitis resolution (53.2% vs 51.4%) along with site-specific resolution of lateral epicondyle enthesitis (84.6% vs 87.1%) and showing relapse after first resolution (21.0% vs 15.6%), as assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Moreover, secukinumab vs adalimumab had a comparable response time to SPARCC enthesitis resolution (113 vs 88 days).
Study details: This post hoc analysis of the EXCEED study included 853 patients with PsA who received either secukinumab (300 mg) or adalimumab (40 mg) over 52 weeks.
Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, USA. C Gaillez and B Parikh declared being current or former employees of Novartis Pharma or Novartis Pharmaceuticals Corporation, and several authors reported ties with various sources, including Novartis.
Source: Kaeley GS et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: A post hoc analysis of the EXCEED study. Rheumatology (Oxford). 2023 (Apr 25). Doi: 10.1093/rheumatology/kead181